MarciaSBroseMDPhD

Cancer Genetics/Cancer Risk Assessment, Endocrine Cancer, Head & Neck Cancer

Director Cancer Services and Vice Chair Medical Oncology, Jefferson Northeast - Sidney Kimmel Cancer Center, Co-Director Comminity Based Clinical Trials, Jefferson Medical College - Sidney Kimmel Cancer Center, Chief of Medical Oncology, Jefferson Torresdale Hospital, Philadelphia, PA

Join to view full profile

Dr. Brose is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Brose's full profile

Already have an account?

Office
Sidney Kimmel Cancer Center - Jefferson Torresdale Hospital
10800 Knights Rd, 3rd Floor
Philadelphia, PA 19104
Phone+1 215-890-3030

Fax+1 215-890-3031

Summary

Director of Cancer Services with focus on delivery of top-tier care in the community setting. Extensive clinical trial experience with leadership in clinical trials for advanced thyroid cancer and genetically targeted therapies in solid tumors. Global leader in the development of advanced thyroid cancer therapeutics, with experience lecturing and teaching on a global level.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1997 - 2000
University of Pennsylvania Health SystemResidency, Internal Medicine, 1995 - 1997
Weill Cornell MedicineClass of 1995

Certifications & Licensure

PA State Medical License 1996 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer Start of enrollment: 2006 Feb 01
Completed
Phase 2
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Start of enrollment: 2010 Nov 01
Active, not recruiting
Phase 2
Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer Start of enrollment: 2015 Mar 01
Withdrawn
Phase 3
LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14
Terminated
Phase 2
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting Start of enrollment: 2014 Jan 01
Active, not recruiting
Phase 2
UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone Start of enrollment: 2017 Apr 03
Suspended
Phase 2
Join now to see all

Publications & Presentations

PubMed

A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer.
Steven G Waguespack, Maria E Cabanillas, Vadim Bernard-Gauthier, Nandini Assar, Gary Bloom
Future Oncology. 2024-11-29
1 citations
Durability of Response With Selpercatinib in Patients With-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
Lori J Wirth, Marcia S Brose, Vivek Subbiah, Francis Worden, Ben Solomon
Journal of Clinical Oncology. 2024-09-20
1 citations
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Marcia S Brose, Jaume Capdevila, Rossella Elisei, Lars Bastholt, Dagmar Führer-Sakel
Endocrine-Related Cancer. 2024-08-01

Journal Articles

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
Targeted Oncogene Therapy Before Surgery in Pediatric Patients with Advanced Invasive Thyroid Cancer at Initial Presentation
Ken Kazahaya, Kara K Prickett, Sanjay R Parikh, Marcia S Brose, JAMA Otolaryngology–Head & Neck Surgery

Lectures

A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer ...
2019 ASCO Annual Meeting - 6/1/2019
Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptoma...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Targeted Oncogene Therapy Before Surgery in Pediatric Patients with Advanced Invasive Thyroid Cancer at Initial PresentationJuly 2020
Join now to see all

Press Mentions

Thyroid Cancer Specialist Joins Sidney Kimmel Cancer Center at JeffersonOctober 22nd, 2021
$Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer$
Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerSeptember 17th, 2021
$Cabozantinib Improved PFS, May Be New Standard for Radioiodine-Refractory Thyroid Cancer$
Cabozantinib Improved PFS, May Be New Standard for Radioiodine-Refractory Thyroid CancerJune 7th, 2021
Join now to see all